|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CCDC34 |
Gene summary for CCDC34 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CCDC34 | Gene ID | 91057 |
| Gene name | coiled-coil domain containing 34 | |
| Gene Alias | L15 | |
| Cytomap | 11p14.1 | |
| Gene Type | protein-coding | GO ID | NA | UniProtAcc | Q96HJ3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 91057 | CCDC34 | HTA11_347_2000001011 | Human | Colorectum | AD | 3.62e-14 | 4.89e-01 | -0.1954 |
| 91057 | CCDC34 | HTA11_696_2000001011 | Human | Colorectum | AD | 7.32e-10 | 4.02e-01 | -0.1464 |
| 91057 | CCDC34 | HTA11_866_2000001011 | Human | Colorectum | AD | 7.47e-06 | 2.69e-01 | -0.1001 |
| 91057 | CCDC34 | HTA11_1391_2000001011 | Human | Colorectum | AD | 2.83e-06 | 4.82e-01 | -0.059 |
| 91057 | CCDC34 | HTA11_546_2000001011 | Human | Colorectum | AD | 2.20e-02 | 3.30e-01 | -0.0842 |
| 91057 | CCDC34 | HTA11_866_3004761011 | Human | Colorectum | AD | 2.12e-04 | 2.79e-01 | 0.096 |
| 91057 | CCDC34 | HTA11_10623_2000001011 | Human | Colorectum | AD | 5.83e-04 | 4.14e-01 | -0.0177 |
| 91057 | CCDC34 | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.15e-06 | 3.27e-01 | 0.0674 |
| 91057 | CCDC34 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 2.71e-08 | 3.32e-01 | 0.294 |
| 91057 | CCDC34 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 9.20e-03 | 8.54e-01 | 0.3487 |
| 91057 | CCDC34 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 1.27e-02 | 1.74e-01 | 0.281 |
| 91057 | CCDC34 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.03e-10 | 5.11e-01 | 0.3859 |
| 91057 | CCDC34 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 4.82e-05 | 2.68e-01 | 0.3005 |
| 91057 | CCDC34 | LZE2T | Human | Esophagus | ESCC | 5.69e-03 | 4.98e-01 | 0.082 |
| 91057 | CCDC34 | LZE4T | Human | Esophagus | ESCC | 1.38e-02 | 1.08e-01 | 0.0811 |
| 91057 | CCDC34 | LZE7T | Human | Esophagus | ESCC | 1.62e-07 | 4.12e-01 | 0.0667 |
| 91057 | CCDC34 | LZE8T | Human | Esophagus | ESCC | 1.18e-02 | 2.63e-01 | 0.067 |
| 91057 | CCDC34 | LZE22T | Human | Esophagus | ESCC | 7.58e-03 | 1.58e-01 | 0.068 |
| 91057 | CCDC34 | LZE24T | Human | Esophagus | ESCC | 4.88e-14 | 6.44e-01 | 0.0596 |
| 91057 | CCDC34 | LZE6T | Human | Esophagus | ESCC | 5.22e-05 | 2.90e-01 | 0.0845 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CCDC34 | SNV | Missense_Mutation | novel | c.655N>A | p.Ala219Thr | p.A219T | Q96HJ3 | protein_coding | deleterious(0.02) | benign(0.019) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| CCDC34 | SNV | Missense_Mutation | novel | c.788N>A | p.Ala263Asp | p.A263D | Q96HJ3 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| CCDC34 | SNV | Missense_Mutation | novel | c.209N>A | p.Leu70His | p.L70H | Q96HJ3 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-AX-A2HJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CCDC34 | SNV | Missense_Mutation | c.1058C>A | p.Ser353Tyr | p.S353Y | Q96HJ3 | protein_coding | deleterious(0.01) | benign(0.371) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
| CCDC34 | SNV | Missense_Mutation | rs762461326 | c.959C>T | p.Pro320Leu | p.P320L | Q96HJ3 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| CCDC34 | SNV | Missense_Mutation | rs371291657 | c.862N>T | p.Arg288Cys | p.R288C | Q96HJ3 | protein_coding | tolerated(0.08) | benign(0.077) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CCDC34 | SNV | Missense_Mutation | novel | c.828T>G | p.Phe276Leu | p.F276L | Q96HJ3 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-D1-A16X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CCDC34 | SNV | Missense_Mutation | rs138159804 | c.422N>A | p.Arg141His | p.R141H | Q96HJ3 | protein_coding | deleterious(0.04) | benign(0) | TCGA-D1-A1O7-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CCDC34 | insertion | Frame_Shift_Ins | rs773019149 | c.731_732insA | p.Asn244LysfsTer3 | p.N244Kfs*3 | Q96HJ3 | protein_coding | TCGA-AP-A1DP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | paclitaxel | PD | ||
| CCDC34 | deletion | Frame_Shift_Del | c.731delN | p.Asn244MetfsTer28 | p.N244Mfs*28 | Q96HJ3 | protein_coding | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |